Role and Expression of MXRA5 in Placental Connective Tissue Remodelling in Preeclampsia

NCT04287998 | Unknown DMC

• 1 other identifier: MXRA5 in preeclampsia
• Study Type: observational
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.To measure the level of expression of MXRA5 and ANXA4 genes in preeclampsia (PE).
2. 2.To detect the effect of heavy metals (lead (Pb) and arsenic (AR)) on these two genes in the pathology of PE.
3. 3.To explore the association of the previous two genes with the heavy metals in link with Phosphoinositide 3-kinases/Protein Kinase B (PI3K/AKT) pathway.
4. 4.To detect Syndecan-1 by immunohistochemical antibodies.
5. 5.To define the role of extracellular matrix remodelling in PE.

Conditions

Pre-Eclampsia

Keywords

MXRA5; ANXA4; Syndecan1; TIMP1; lead; arsenic

Outcome Measures

Primary Outcomes (1)

• Gene expression level of MXRA5 gene in PE patients and control group

  1 year

Secondary Outcomes (4)

• Gene expression level of ANXA4 in PE patients and control group.

  1 year

• Gene expression level of TIMP1 gene in PE patients and control group.

  1 year

• Protein level measurement of phosphorylated AKT(pAKT) in PE patients and control group.

  1 year

• Measurement of lead and arsenic level in PE patients and control group.

  1 year

Study Arms (2)

1

PE group

2

Control group

Eligibility Criteria

• Age: 20 Years - 40 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

• Placental tissue samples (surgically obtained during the caesarean section from 50 pregnant women) will be selected: * 25 PE patients undergoing caesarean section following diagnosis by blood pressure measurement and urine analysis. * 25 controls undergoing caesarean section. * Placental samples are 4x6 cm in dimension. Blood samples: Six milliliters of maternal blood was collected in plastic tubes. Urinary samples.

You may qualify if:

• Gestational age is \>28 weeks.
• Clinically diagnosed PE with blood pressure (≥140/90 mmHg) and proteinuria (≥300mg/dl).
• Healthy pregnant women (age matched control group).

You may not qualify if:

• Gestational diabetes.
• Pregestational hypertension (essential hypertension) or proteinuria.
• Systemic illness.
• Vaginal infection.
• Major known fetal or chromosomal anomalies.
• Multiple gestations.
• Intrauterine infections.
• Preterm premature rupture of membranes.
• Sepsis.
• Fever.
• Colitis ulcerosa.
• Crohn's disease.
• Chronic renal disease.
• Rheumatic disease.

Sponsors & Collaborators

• Assiut University: lead

Biospecimen

Retention: SAMPLES WITH DNA

Placental Tissue samples collection: • Placental tissue samples (surgically obtained during the caesarean section from 50 pregnant women) will be selected: * 25 PE patients undergoing the caesarean section following confirmation of diagnosis clinically by blood pressure measurement and by urine analysis to detect the proteinuria. * 25 control women undergoing the caesarean section. Blood samples. Urinary samples.

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Central Study Contacts

Shimaa A Abd Elrahman, assistant lecturer

CONTACT

01069873568; shimo_ahmed_89@yahoo.com

Mona A El Baz, Professor

CONTACT

01005800409

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: February 22, 2020
• First Posted: February 27, 2020
• Study Start: April 1, 2020
• Primary Completion: April 1, 2021
• Study Completion: May 1, 2021
• Last Updated: February 27, 2020

Record last verified: 2020-02